Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial
用户k7g3AjDeE8DM
2个月前
88
10
已完结
1. 系统已在2025-08-01 17:43:57对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.2337/dc25-0942
其他信息:
出版社: American Diabetes Association
作者: Yu Mi Kang; Robert P. Giugliano; Xinhui Ran; Prakash Deedwania; Gaetano M. De Ferrari; Jyothis T. George; Ioanna Gouni-Berthold; Gabriel Paiva da Silva Lima; Yehuda Handelsman; Basil S. Lewis; E. Magnus Ohman; Huei Wang; J. Antonio G. López; Maria Laura Monsalvo; Marc S. Sabatine; Lawrence A. Leiter
全文下载地址: https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc25-0942/823498/dc250942.pdf
